课题基金 / 基金详情

CARCINOGENESIS AND NOVEL THERAPEUTICS IN ORAL CANCER

CARCINOGENESIS AND NOVEL THERAPEUTICS IN ORAL CANCER
口腔癌的致癌作用和新疗法
批准号:
6487804
负责人:
EVERETT E. VOKES
金额:
$42.63万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
1996
资助国家:
美国
项目状态:
已结题
起止时间:
1996-09-30 至 2002-07-31

项目摘要

项目成果

EVERETT E. VOKES的其他基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
There is a long history of oral cancer research in the Chicago area. In this application, the University of Chicago and Northwestern University are combining their efforts in laboratory and clinical sciences to foster interactions between laboratory scientists and clinical investigators, to generate new treatment hypothesis and conduct translational research in oral cancer. We will seek to optimize currently available therapy and improve the rehabilitation of the oral cancer patient. Our long-term goals are to identify new approaches to early diagnosis and more successful therapy based on an understanding of the molecular mechanisms underlying this disease. We will support pilot projects and the rapid generation of new clinical laboratory hypotheses utilizing developmental research funds provided by the grant and supplemented by the participating institutions and provide education and training in oral cancer research for basic and clinical investigators. The principal investigators have a long history of collaboration and have also conducted independent studies of oral carcinogenesis and cancer therapy and rehabilitation. Four projects are described in this application Project #1 will examine mechanisms underlying oral carcinogenesis that may identify tools for future early detection. Project #2 will study the role of apoptosis in oral carcinogenesis. Project #3 will study molecular pharmacokinetics of chemotherapy with concomitant radiotherapy in order to deliver more effective and less toxic therapy. Project #4 will measure organ function and rehabilitation in patients treated with curative intent chemoradiotherapy. Three pilot projects are also included which will be funded by the grant and matching funds made available by the two participating institutions. These activities will be supported by three cores. The administrative core, the biostatistical, data management and clinical core, and the tissue procurement and laboratory core. Core A, the administrative core will monitor ongoing projects, assure successful and timely performance of scientific tasks and interact with the internal and external advisory boards. Core B, the biostatistical data management and clinical core will provide expertise in data collection and analysis. Core C, the laboratory core will be responsible for the appropriate collection, preparation and distribution of human tissues required for ongoing projects.
期刊论文(19)
专著(0)
科研奖励(0)
会议论文
Tumor production of angiostatin is enhanced after exposure to TNF-alpha.
暴露于 TNF-α 后,肿瘤产生血管抑制素会增强。
DOI: 10.1002/ijc.1629
发表时间: 2002
期刊: International journal of cancer
影响因子: 6.4
作者: [Mauceri,HelenaJ, Seetharam,Saraswathy, Beckett,MichaelA, Lee,JohnY, Gupta,VinayK, Gately,Stephen, Stack,MSharon, Brown,CharlesK, Swedberg,Kirsten, Kufe,DonaldW, Weichselbaum,RalphR]
通讯作者: Weichselbaum,RalphR
Volumetric visualization of head and neck CT data for treatment planning.
用于治疗计划的头颈 CT 数据的体积可视化。
DOI: 10.1016/s0360-3016(99)00042-5
发表时间: 1999
期刊: International journal of radiation oncology, biology, physics
影响因子: --
作者: [Lee,JS, Jani,AB, Pelizzari,CA, Haraf,DJ, Vokes,EE, Weichselbaum,RR, Chen,GT]
通讯作者: Chen,GT
Radiation therapy with concomitant hydroxyurea and fluorouracil in stage II and III head and neck cancer.
II 期和 III 期头颈癌联合羟基脲和氟尿嘧啶的放射治疗。
DOI: 10.1200/jco.1999.17.2.638
发表时间: 1999
期刊: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
影响因子: --
作者: [Haraf,DJ, Kies,M, Rademaker,AW, Stenson,K, Mittal,B, Pelzer,H, Wenig,B, Witt,ME, Sulzen,L, Weichselbaum,RR, Vokes,EE]
通讯作者: Vokes,EE
Phase I study of eniluracil, a dihydropyrimidine dehydrogenase inactivator, and oral 5-fluorouracil with radiation therapy in patients with recurrent or advanced head and neck cancer.
恩尿嘧啶(一种二氢嘧啶脱氢酶灭活剂)和口服 5-氟尿嘧啶联合放射治疗治疗复发或晚期头颈癌患者的 I 期研究。
DOI: --
发表时间: 1999
期刊: Clinical cancer research : an official journal of the American Association for Cancer Research
影响因子: --
作者: [Humerickhouse,RA, Dolan,ME, Haraf,DJ, Brockstein,B, Stenson,K, Kies,M, Sulzen,L, Ratain,MJ, Vokes,EE]
通讯作者: Vokes,EE
PROGRAM 4 (CLINICAL AND EXPERIMENTAL THERAPEUTICS)
  • 批准号:
    7714258
  • 项目类别:
  • 资助金额:
    $2.54万
  • 财政年份:
    2008
  • 负责人:
    EVERETT E. VOKES
  • 依托单位:
Early Therapeutics Development with Phase II Emphasis
  • 批准号:
    7789051
  • 项目类别:
  • 资助金额:
    $65.41万
  • 财政年份:
    2006
  • 负责人:
    EVERETT E. VOKES
  • 依托单位:
EARLY THERAPEUTICS DEVELOPMENT WITH PHASE II EMPHASIS
  • 批准号:
    7543379
  • 项目类别:
  • 资助金额:
    $173.73万
  • 财政年份:
    2006
  • 负责人:
    EVERETT E. VOKES
  • 依托单位:
    --
TAS:: 75 0850 ::TAS RECOVERY ACT - ACTNOW CLINICAL TRIAL 8418 UNDER
  • 批准号:
    7933245
  • 项目类别:
  • 资助金额:
    $65.0万
  • 财政年份:
    2006
  • 负责人:
    EVERETT E. VOKES
  • 依托单位: